TScan Therapeutics (TCRX) Institutional Ownership $7.27 +0.09 (+1.25%) (As of 07/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for TScan Therapeutics (NASDAQ:TCRX)CurrentInstitutional OwnershipPercentage82.83%Number ofInstitutional Buyers(last 12 months)10TotalInstitutional Inflows(last 12 months)$12.50MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$68.21K Get TCRX Insider Trade Alerts Want to know when executives and insiders are buying or selling TScan Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data TCRX Institutional Buying and Selling by Quarter Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report TScan Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/26/2024 Bank of New York Mellon Corp116,658$682K0.0%N/A0.221% 5/10/2024Vanguard Group Inc.1,808,152$14.36M0.0%+1.1%3.776% 5/10/2024Tocqueville Asset Management L.P.212,200$1.69M0.0%N/A0.443% 4/17/2024Cannon Global Investment Management LLC17,500$139K0.4%N/A0.037% 2/14/2024Pale Fire Capital SE21,573$126K0.0%+30.2%0.045% 2/12/2024Letko Brosseau & Associates Inc.20,700$121K0.0%-36.1%0.043% Get the Latest News and Ratings for TCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024abrdn plc200,000$1.17M0.0%N/A0.418% 11/14/2023Pale Fire Capital SE16,575$42K0.0%N/A0.035% 11/9/2023Letko Brosseau & Associates Inc.32,400$83K0.0%N/A0.068% 8/15/2023BVF Inc. IL2,989,474$7.47M0.2%N/A12.338% 8/10/2023Monashee Investment Management LLC400,000$1M0.2%N/A1.651% 7/26/2023Privium Fund Management B.V.15,825$40K0.0%N/A0.065% 5/10/2023Simplify Asset Management Inc.546,916$1.15M0.2%N/A2.257% 2/15/2023Tang Capital Management LLC514,655$798K0.1%-7.8%2.137% 11/16/2022Alphabet Inc.1,077,080$3.29M0.2%N/A4.482% 11/15/2022Tang Capital Management LLC557,915$1.70M0.2%-25.4%2.322% 11/4/2022Prudential Financial Inc.11,000$34K0.0%N/A0.046% 11/1/2022Privium Fund Management UK Ltd15,825$48K0.1%N/A0.066% 5/17/2022RA Capital Management L.P.1,021,764$2.86M0.1%-18.6%4.299% 5/17/2022Hhlr Advisors LTD.669,513$1.88M0.0%-47.8%2.817% 4/26/2022Marquette Asset Management LLC28,895$81K0.0%+33.7%0.122% 2/15/2022Deer Management Co. LLC1,245,505$5.61M0.1%N/A5.240% 2/15/2022Adage Capital Partners GP L.L.C.550,000$2.48M0.0%+10.8%2.314% 1/19/2022Marquette Asset Management LLC21,618$97K0.0%N/A0.091% 11/16/2021Schonfeld Strategic Advisors LLC22,200$185K0.0%N/A0.093% 11/16/2021Wellington Management Group LLP139,566$1.16M0.0%N/A0.582% 11/15/2021RA Capital Management L.P.1,255,317$10.47M0.1%N/A5.238% 11/15/2021 Caas Capital Management LP75,000$626K0.0%N/A0.313% 11/12/2021DC Investments Management LLC35,563$297K0.6%N/A0.148% 11/12/2021DC Funds LP630,000$5.25M20.6%N/A2.629% 11/9/2021BlackRock Inc.1,500,577$12.52M0.0%N/A6.261% 11/9/2021Monashee Investment Management LLC100,000$834K0.2%N/A0.417% (Data available from 1/1/2016 forward) TCRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TCRX shares? During the previous two years, 15 institutional investors and hedge funds held shares of TScan Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($14.36M), BVF Inc. IL ($7.47M), Alphabet Inc. ($3.29M), Tocqueville Asset Management L.P. ($1.69M), abrdn plc ($1.17M), Simplify Asset Management Inc. ($1.15M), and Monashee Investment Management LLC ($1M).Learn more on TCRX's institutional investors. What percentage of TScan Therapeutics stock is owned by institutional investors? 82.83% of TScan Therapeutics stock is owned by institutional investors. Learn more on TCRX's institutional investor holdings. Which institutional investors have been buying TScan Therapeutics stock? Of the 14 institutional investors that purchased TScan Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($2.99M), Alphabet Inc. ($1.08M), Simplify Asset Management Inc. ($546.92K), Monashee Investment Management LLC ($400K), Tocqueville Asset Management L.P. ($212.20K), abrdn plc ($200K), and Bank of New York Mellon Corp ($116.66K). How much institutional buying is happening at TScan Therapeutics? Institutional investors have bought a total of 5,676,451 shares in the last 24 months. This purchase volume represents approximately $17.01M in transactions. Which TScan Therapeutics major shareholders have been selling company stock? The following institutional investors have sold TScan Therapeutics stock in the last 24 months: Tang Capital Management LLC ($233.15K), and Letko Brosseau & Associates Inc. ($11.70K). How much institutional selling is happening at TScan Therapeutics? Institutional investors have sold a total of 244,845 shares in the last 24 months. This volume of shares sold represents approximately $714.41K in transactions. Related Companies: Nkarta Institutional Ownership Adaptimmune Therapeutics Institutional Ownership Voyager Therapeutics Institutional Ownership Absci Institutional Ownership Adaptive Biotechnologies Institutional Ownership Fate Therapeutics Institutional Ownership CASI Pharmaceuticals Institutional Ownership Instil Bio Institutional Ownership Champions Oncology Institutional Ownership Achilles Therapeutics Institutional Ownership This page (NASDAQ:TCRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.